一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Heterogenous profiles between primary lung cancers and paired brain metastases reveal tumor evolution.
Heterogenous profiles between primary lung cancers and paired brain metastases reveal tumor evolution.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究通过对配对的原发性肺癌和 BM 进行多维分析,揭示了时间和空间因素对肿瘤异质性演化的重要意义,也为制定 BM 的个体化治疗策略提供了新的见解。
脑转移(BM)是最常见的中枢神经系统(CNS)恶性肿瘤,疾病进展迅速且预后极差。原发肺癌与脑转移间的异质性导致原发灶与脑转移灶对辅助治疗的应答疗效不同。然而,两者异质性的程度及其演化过程仍知之甚少。
为深入了解单个患者层面的肿瘤间异质性及其演化过程,研究回顾性分析10例患者的26份肿瘤样本,包括配对原发肺癌和脑转移灶。其中一位患者曾因不同位置的脑转移灶接受4次手术,并对原发灶接受1次手术。采用全外显子组测序(WES)和免疫组化分析原发肺癌与脑转移灶之间的基因组和免疫异质性。
除脑转移灶继承原发肺癌的基因组和分子表型外,还观察到大量独特的基因组和分子表型,揭示肿瘤演化具有难以预料的复杂性,单个患者不同病灶间也存在广泛异质性。通过分析一例多发转移病例(病例3)癌细胞亚克隆组成,研究发现4个在空间和时间上相互独立的脑转移灶具有相似的多种亚克隆簇,呈现多克隆播散特征。研究还证实,与配对原发肺癌相比,脑转移灶的免疫检查点分子PD-L1表达(P=.0002)和TIL(肿瘤浸润淋巴细胞)密度(P=.0248)显著较低。此外,原发肿瘤和配对脑转移灶的肿瘤微血管密度(MVD)也存在差异,表明时间和空间差异对脑转移异质性演化有重大影响。
本研究通过多维度分析配对原发肺癌与脑转移灶,揭示了时间和空间因素在肿瘤异质性演化中的重要性,并为制定脑转移个体化治疗策略提供了新见解。
Brain metastases (BMs) are the most common central nervous system (CNS) malignant tumors, with rapid disease progression and extremely poor prognosis. The heterogeneity between primary lung cancers and BMs leads to the divergent efficacy of the adjuvant therapy response to primary tumors and BMs. However, the extent of heterogeneity between primary lung cancers and BMs, and the evolutionary process remains little known.
To deeply insight into the extent of inter-tumor heterogeneity at a single-patient level and the process of these evolutions, we retrospectively analyzed a total of 26 tumor samples from 10 patients with matched primary lung cancers and BMs. One patient underwent four times brain metastatic lesion surgery with diverse locations and one operation for the primary lesion. The genomic and immune heterogeneity between primary lung cancers and BMs were evaluated by utilizing whole-exome sequencing (WESeq) and immunohistochemical analysis.
In addition to inheriting genomic phenotype and molecular phenotype from the primary lung cancers, massive unique genomic phenotype and molecular phenotype were also observed in BMs, which revealed unimaginable complexity of tumor evolution and extensive heterogeneity among lesions at a single-patient level. By analysis of a multi-metastases case (Case 3) of cancer cells' subclonal composition, we found similar multiple subclonal clusters in the four spatial and temporal isolated brain metastatic focus, with the characteristics of polyclonal dissemination. Our study also verified that the expression level of immune checkpoints-related molecule Programmed Death-Ligand 1 (PD-L1) (P = 0.0002) and the density of tumor-infiltrating lymphocytes (TILs) (P = 0.0248) in BMs were significantly lower than that in paired primary lung cancers. Additionally, tumor microvascular density (MVD) also differed between primary tumors and paired BMs, indicating that temporal and spatial diversity profoundly contributes to the evolution of BMs heterogeneity.
Our study revealed the significance of temporal and spatial factors to the evolution of tumor heterogeneity by multi-dimensional analysis of matched primary lung cancers and BMs, which also provided novel insight for formulating individualized treatment strategies for BMs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。